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ABSTRACT 
CONTEXT AND OBJECTIVE: Polymorphisms in genes involved in folate metabolism may modulate the maternal risk of Down syndrome (DS). This study 
evaluated the influence of a 19-base pair (bp) deletion polymorphism in intron-1 of the dihydrofolate reductase (DHFR) gene on the maternal risk 
of DS, and investigated the association between this polymorphism and variations in the concentrations of serum folate and plasma homocysteine 
(Hcy) and plasma methylmalonic acid (MMA).
DESIGN AND SETTING: Analytical cross-sectional study carried out at Faculdade de Medicina de São José do Rio Preto (Famerp). 
METHODS: 105 mothers of individuals with free trisomy of chromosome 21, and 184 control mothers were evaluated. Molecular analysis on the 
polymorphism was performed using the polymerase chain reaction (PCR) through differences in the sizes of fragments. Folate was quantified by 
means of chemiluminescence, and Hcy and MMA by means of liquid chromatography and sequential mass spectrometry.
RESULTS: There was no difference between the groups in relation to allele and genotype frequencies (P = 0.44; P = 0.69, respectively). The folate, 
Hcy and MMA concentrations did not differ significantly between the groups, in relation to genotypes (P > 0.05).
CONCLUSIONS: The 19-bp deletion polymorphism of DHFR gene was not a maternal risk factor for DS and was not related to variations in the 
concentrations of serum folate and plasma Hcy and MMA in the study population.
RESUMO
CONTEXTO E OBJETIVO: Polimorfismos em genes do metabolismo do folato podem modular o risco materno para síndrome de Down (SD). Este 
estudo avaliou a influência do polimorfismo de deleção de 19 pares de base (pb) no íntron 1 do gene dihidrofolato redutase (DHFR) no risco 
materno para SD e investigou a associação entre esse polimorfismo e variações nas concentrações de folato sérico, homocisteína (Hcy) e ácido 
metilmalônico (MMA) plasmáticos. 
TIPO DE ESTUDO E LOCAL: Estudo transversal analítico realizado na Faculdade de Medicina de São José do Rio Preto (Famerp).
MÉTODOS: 105 mães de indivíduos com trissomia livre do cromossomo 21 e 184 mães controles foram avaliadas. A análise molecular do 
polimorfismo foi realizada pela reação em cadeia da polimerase (PCR) por diferença de tamanho dos fragmentos. O folato foi quantificado por 
quimioluminescência, e Hcy e MMA foram determinados por cromatografia líquida/espectrometria de massas sequencial.
RESULTADOS: Não houve diferença entre os grupos em relação às frequências alélica e genotípica (P = 0,44; P = 0,69, respectivamente). As 
concentrações de folato, Hcy e MMA não mostraram diferença significativa entre os genótipos, entre grupos (P > 0,05).
CONCLUSÕES: O polimorfismo de deleção de 19 pb do gene DHFR não é um fator de risco materno para SD e não está relacionado com variações 
nas concentrações de folato sérico, Hcy e MMA plasmáticos na população estudada.
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INTRODUCTION
Down syndrome (DS) is a genetic disease characterized, in most 
cases, by free trisomy of chromosome 21 caused by non-disjunction 
in maternal meiosis.1,2 James et al.3 were the first to observe an in-
creased risk of chromosome non-disjunction due to abnormal folate 
metabolism, and this is responsible for abnormalities in the pattern 
of deoxyribonucleic acid (DNA) methylation. 
Folate plays an essential role in several complex metabolic path-
ways, including those leading to DNA synthesis or conversion of 
homocysteine (Hcy) to methionine, which is then used to form 
the main DNA methylating agent: S-adenosyl methionine (SAM).4 
Studies have shown that polymorphisms in genes encoding enzymes 
involved in this metabolic pathway, and higher concentrations of 
Hcy and lower folate concentrations, modulate the maternal risk 
factor for DS.5-8 
The dihydrofolate reductase (DHFR) gene encodes an enzyme that 
catalyzes the conversion of dihydrofolate (DHF) into tetrahydrofo-
late (THF). It is also needed for the intracellular conversion of syn-
thetic folic acid (which is consumed in supplements and fortified 
foods) to DHF and THF, which are the forms that participate in fo-
late and Hcy metabolism.9 Johnson et al.10 described a 19-base pair 
(bp) deletion polymorphism in intron-1 of the DHFR gene and hy-
pothesized that this polymorphism could be functional because the 
deletion removes a possible transcription factor binding site that af-
fects gene regulation.
A study on the mothers of individuals with spina bifida showed 
that the messenger ribonucleic acid (mRNA) expression of the 
DHFR gene was 50% higher in the del/del genotype than in the ins/
ins genotype.11 Moreover, in a study on women with breast cancer, 
Xu et al.12 also observed mRNA concentrations that were 2.4 and 
4.8 times higher in individuals with the ins/del and del/del geno-
types, respectively, in comparison with individuals with the ins/ins 
genotype. 
This polymorphism has been correlated with modulation of the 
metabolites involved in the folate pathway. Gellekink et al.13 report-
ed that the del/del genotype was associated with lower plasma Hcy 
concentrations, but did not find any association between this geno-
type and concentrations of serum and erythrocyte folate. Another 
study did not find any effect on Hcy concentration, but found in-
creased plasma and erythrocyte folate levels in del/del individuals.9
To the best of our knowledge, no published studies have evalu-
ated the association of 19-bp deletion polymorphism in intron-1 of 
the DHFR gene with the maternal risk of DS. 
OBJECTIVES
This study aimed to evaluate the influence of the 19-bp deletion 
polymorphism in intron-1 of the DHFR gene on the maternal risk 
of DS and to investigate the association between this polymorphism 
and variations in the concentrations of serum folate and plasma Hcy 
and methylmalonic acid (MMA), an indicator of vitamin B12 status.
METHODS
This analytical cross-sectional study was carried out at Faculdade 
de Medicina de São José do Rio Preto (Famerp) and was composed 
of a case group formed by 105 mothers of DS children with karyo-
typically confirmed free trisomy 21  and a control group consisting 
of 184 mothers with healthy offspring and no experience of miscar-
riages. Informed consent was obtained from all these volunteers. 
The mothers’ median ages at delivery (maternal age) and when 
the blood samples were obtained (age at presentation) were 30.4 
years (range 12.9-46.3 years) and 43.1 years (range 22.5-69.3 years) 
in the case group, respectively, and 26.4 years (range 15.4-40.7 
years) and 36.1 years (13.2-68.8 years) in the control group. The 
maternal age was calculated as the age of the mother at the birth of 
the DS child for the case group, and the age at the birth of the last 
child for the control group.
Fasting blood samples were collected for molecular and bio-
chemical analysis (serum folate and plasma Hcy and MMA). DNA 
extraction was performed as previously described by Miller et al.14 
and the 19-bp deletion polymorphism in DHFR gene was analyzed 
by means of the polymerase chain reaction (PCR) using the differ-
ence in the size of fragments to determinate the genotypes, using 
primer sequences described by Dulucq et al.15 The PCR-amplified 
fragments were analyzed by means of electrophoresis in 6% poly-
acrylamide gel. 
Folate was quantified by means of chemiluminescence (Immulite 
Kit, DPC Medlab, Brazil) and liquid chromatography-tandem mass 
spectrometry was used to determine the plasma Hcy and MMA con-
centrations, as previously described.16-18 
The existence of Hardy-Weinberg equilibrium was tested using 
the chi-square test, and genotype frequencies among the case and 
control mothers were compared by means of the likelihood ratio test 
and logistic regression. Mood’s median test was used to investigate 
the association between the polymorphism in the DHFR gene and 
variations in the serum folate and plasma Hcy and MMA concentra-
tions. P values ≤ 0.05 were taken to be statistically significant.
RESULTS
Table 1 presents the allele and genotype frequencies of 19-bp 
deletion polymorphism in the DHFR gene in the case and control 
groups. The allele frequencies were in Hardy-Weinberg equilibrium 
in both groups, and there were no differences in allele and genotype 
frequencies be tween the DS and control mothers. There were no sig-
nificant differences in the distributions of serum folate and plasma 
Hcy and MMA concentrations between the genotypes of the case 
and control groups (P > 0.05) (Table 2).
DISCUSSION
Independent of maternal age, DS has been associated with oth-
er etiological factors. Studies have shown that cell folate deficiencies 
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DHFR Case mothers Control mothers P
Allele frequencies
ins 0.50 0.46
0.44
del 0.50 0.54
Genotype frequencies
ins/ins 0.26 0.23
0.69ins/del 0.48 0.46
del/del 0.26 0.31
Table 1. Allele and genotype frequencies of 19-bp deletion polymorphism 
in intron-1 of the dihydrofolate reductase (DHFR) gene in the case and 
control groups of mothers
Concentration ins/ins ins/del del/del P
Case group
Folate (ng/ml) 14.10 11.85 12.30 0.57
Hcy (µmol/l) 6.21 7.25 5.34 0.20
MMA (µmol/l) 0.18 0.17 0.17 0.41
Control group
Folate (ng/ml) 15.60 14.10 14.60 0.74
Hcy (µmol/l) 8.85 8.15 8.19 0.29
MMA (µmol/l) 0.15 0.14 0.14 0.98
Table 2. Distribution of serum folate, plasma homocysteine (Hcy) and 
plasma methylmalonic acid (MMA) concentrations according to genotypes 
of the 19-bp deletion polymorphism in intron-1 of the dihydrofolate 
reductase (DHFR) gene, in the case  and control groups of mothers
result in aberrant DNA methylation, point mutations, chromosome 
breakage, defective chromosome recombination and aneuploidy of 
chromosome 21.19-21 Folate metabolism plays an important role in 
the synthesis of nucleotides and of SAM, which is the main donor 
of methyl groups for DNA, protein and phospholipid methylation 
reactions.22 Many genes are involved in these metabolic pathways 
and, in 1999, James et al.3 hypothesized that abnormalities in DNA 
methylation are a potential causative mechanism of meiotic non-dis-
junction. Their report stimulated considerable investigation into the 
possible role of folate metabolism in relation to the risk of having a 
DS child, and several studies have found this association.5-8,23,24
One important gene that is involved in this metabolism is 
DHFR, which encodes the enzyme responsible for reducing folic 
acid in THF.9 A common polymorphism in this gene, 19-bp deletion 
polymorphism in intron-1, has been correlated with modulation of 
the maternal risk of neural tube defects (NTDs),10,11 and of the con-
centrations of the metabolites involved in the folate pathway.9,13,25 
Originally, Johnson et al.10 observed that the del/del genotype 
was related to increased risk of having offspring with spina bifida. 
On the other hand, another study has suggested that the del/del 
genotype has a protective effect and decreases the maternal risk of 
spina bifida,11 while yet another study reported no effect.26 Thus, 
the contribution of the 19-bp deletion polymorphism in intron-1 
of the DHFR gene towards the risk of NTDs remains a matter of 
controversy.
Considering the high frequency of DS cases in families with high-
er risk of NTDs, and vice versa,27 and the fact that both diseases are 
influenced by the same genetic determinants of folate metabolism,28 
it is possible that the 19-bp deletion polymorphism in intron-1 of 
the DHFR gene modulates the maternal risk of DS. However, in the 
present study, no association between this polymorphism and the 
maternal risk of DS was observed. In addition, no association was 
observed between the 19-bp deletion polymorphism of the DHFR 
gene and the folate, Hcy and MMA concentrations in the present 
study, although the presence of the polymorphic allele has been as-
sociated with increased concentrations of serum and erythrocyte fo-
late, and reduction in the concentration of plasma Hcy in previous 
studies.9,13,25 The variations between studies may have been caused by 
nutritional and ethnic differences between the populations studied, 
as well as differences in sample sizes and other genetic factors.
One of the limitations of our study is that serum folate was quan-
tified instead of erythrocyte folate. The erythrocyte folate content 
represents the time average of the folate concentrations occurring at 
the genesis of each red cell and is therefore less susceptible to rapid 
changes in diet.29,30 One study observed a significant difference in 
erythrocyte folate quantification between case and control mothers, 
which was not observed when quantifying serum folate.31 However, 
quantification of erythrocyte folate is more complex to perform29.30 
and, for this reason, many studies have measured serum folate.5,32-34 In 
addition, a recent study has indicated that serum folate assays provide 
information that is equivalent to erythrocyte folate measurements for 
attempting to determine folate deficiency.30
CONCLUSIONS
In this study, no evidence for an association between the 19-bp 
deletion polymorphism in intron-1 of the DHFR gene and the ma-
ternal risk of DS was observed. Moreover, this polymorphism was 
not related to variations in the concentrations of serum folate and 
plasma Hcy and MMA in the study population.
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